Biogen Idec Ma Inc.

Other

Revitope Limited

Biogen Ma Inc.

Werner Meier

Jeffrey L Browning

Alexey Alexandrovich Lugovskoy

Ellen A Garber

Christopher D Benjamin

Konrad Miatkowski

R Blake Pepinsky

Paul H Weinreb

Dingyi Wen

Laura Silvian

Daniel H S Lee

Jane K Relton

Graham K Farrington

Xinzhong Wang

Martin Preyer

David Evans

Emma Geiger

Allison Colthart

Patrick Wiencek

Pamela Weinstein

John K Eldredge

Evan Beckman

Justin McCue

Jonathan Romero

Stephen Notarnicola

Richard Macniven

Daniel Hs Lee

Daniel HS Lee

A Twin Immune Cell Engager (TWICE) is a kit or composition for treating cancer comprising a first component and second component. Each component comprises a targeting moiety that binds a tumor antigen expressed by the cancer or an antigen expressed by a non-cancer cell in the tumor microenvironment. In some embodiments, the first and second components each comprise an immune cell binding domain capable of immune cell binding activity when binding the immune cell binding domain in the other component, and a complementary binding domain capable of binding to a complementary antigen when binding the complementary binding domain in the other component. In some embodiments, the first and/or second components comprise a complementary functional domain with activity when targeted to the cancer cell or its microenvironment.

Twin immune cell engager

Disclosed are immunogenic Nogo receptor-1 polypeptides, Nogo receptor-1 antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof and nucleic acids encoding the same. Also disclosed are Nogo receptor antagonist polynucleotides. Also disclosed are compositions comprising, and methods for making and using, such Nogo receptor antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof, nucleic acids encoding the same and antagonist polynucleotides.

Nogo receptor antagonists and methods of increasing neurite outgrowth

Methods for high level expression of active lymphotoxin-&#x3b2; receptor immunoglobulin chimeric proteins and their purification.

Method for increasing expression of active tumor necrosis factor receptor family member-Ig fusion proteins

Nogo receptor antagonists

The compositions and methods of the present invention are based, in part, on our discovery that an effector function mediated by an Fc-containing polypeptide can be altered by modifying one or more amino acid residues within the polypeptide (by, for example, electrostatic optimization). The polypeptides that can be generated according to the methods of the invention are highly variable, and they can include antibodies and fusion proteins that contain an Fc region or a biologically active portion thereof.

Neonatal Fc receptor (FcRn)-binding polypeptide variants, dimeric Fc binding proteins and methods related thereto

This invention relates to methods of treating disease with soluble inhibitors of the lymphotoxin pathway having improved properties. This invention also relates to improved LTBR-Ig fusion proteins, and pharmaceutical compositions thereof.

Compositions comprising variant LT-B-R-IG fusion proteins

Method for the high level expression of active tumor necrosis receptor family member immunoglobulin fusion proteins

Active lymphotoxin-&#x3b2; receptor immunoglobulin chimeric protein compositions

This invention relates to compositions and methods useful for activating LT-&#x3b2; receptor signaling, which in turn elicits potent anti-proliferative effects on tumor cells. More particularly, this invention relates to lymphotoxin heteromeric complexes formed between lymphotoxin-&#x3b1; and multiple subunits of lymphotoxin-&#x3b2;, which induce cytotoxic effects on tumor cells in the presence of lymphotoxin-&#x3b2; receptor activating agents. Also within the scope of this invention are antibodies directed against the lymphotoxin-&#x3b2; receptor which act as lymphotoxin-&#x3b2; receptor activating agents alone or in combination with other lymphotoxin-&#x3b2; receptor activating agents either in the presence or absence of lymphotoxin-&#x3b1;/&#x3b2; complexes. A screening method for selecting such antibodies is provided. This invention also relates to compositions and methods using cross-linked anti-lymphotoxin-&#x3b2; receptor antibodies either alone or in the presence of other lymphotoxin-&#x3b2; receptor activating agents to potentiate tumor cell cytotoxicity.

Anti-lymphotoxin-&#x3b2; receptor antibodies as anti-tumor agents

This invention relates to compositions and methods useful for treating or reducing the advancement, severity or effects of neoplasia by the administration of at least two or more lymphotoxin beta receptor (LT-&#x3b2; receptor) activating agents where at least one LT-&#x3b2; receptor activating agent is an anti-LT-&#x3b2; receptor antibody.

Anti-lymphotoxin-beta receptor antibodies as anti-tumor agents

This invention relates to compositions and methods useful for activating LT-&bgr; receptor signaling, which in turn elicits potent anti-proliferative effects on tumor cells. More particularly, this invention relates to lymphotoxin heteromeric complexes formed between lymphotoxin-&agr; and multiple subunits of lymphotoxin-&bgr;, which induce cytotoxic effects on tumor cells in the presence of lymphotoxin-&bgr; receptor activating agents. Also within the scope of this invention are antibodies directed against the lymphotoxin-&bgr; receptor which act as lymphotoxin-&bgr; receptor activating agents alone or in combination with other lymphotoxin-&bgr; receptor activating agents either in the presence or absence of lymphotoxin-&agr;/&bgr; complexes. A screening method for selecting such antibodies is provided. This invention also relates to compositions and methods using cross-linked anti-lymphotoxin-&bgr; receptor antibodies either alone or in the presence of other lymphotoxin-&bgr; receptor activating agents to potentiate tumor cell cytotoxicity.

Lymphotoxin-&agr;/&bgr; complexes and anti-lympotoxin-&bgr; receptor antibodies as anti-tumor agents

Growing community of inventors

Burlington, MA, United States of America

Werner Meier